Compare iShares International Treasury Bond ETF (IGOV) vs Eli Lilly And Co (LLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares International Treasury Bond ETF vs Eli Lilly And Co — how do they compare? iShares International Treasury Bond ETF trades at $39.67 (market cap $1.30B), while Eli Lilly And Co trades at $1,174.47 (market cap $1.04T). The key difference: Eli Lilly And Co is far larger — about 800× iShares International Treasury Bond ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares International Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares International Treasury Bond ETF for 92 Days and Eli Lilly And Co for 93 Days on average.
| IGOV | LLY | |
|---|---|---|
Market Cap | $1.30B | $1.04T |
Volume | 693,740 | 3,064,878 |
Sector | Fixed Income | Health |
52-Week High | $42.99 | $1.28K |
52-Week Low | $39.65 | $799.57 |
Typical Hold Time | 92 Days | 93 Days |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IGOV trades at $39.67, down 0.08% with a bearish technical signal from moving averages, while oscillators are neutral. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights rising global bond yields, which may impact interest rate-sensitive stocks.
The outlook is cautious due to missing financial data and bearish technicals. Risks include macroeconomic pressure from higher yields, while opportunities depend on future earnings visibility. Investors need updated financials to assess valuation and growth prospects accurately.
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →
